Common heart pill may hold key to fighting silent liver scourge
NCT ID NCT04679376
Summary
This study is testing if a widely used cholesterol-lowering drug, atorvastatin (Lipitor), can safely improve liver health in adults with NASH, a serious form of fatty liver disease that can lead to scarring. About 70 participants with confirmed liver damage will receive either the drug or a placebo for nearly a year to see if it reduces liver inflammation and scarring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.